Deciphera Pharmaceuticals LLC (DCPH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH136725D
- Pages: 43
- October 2018
- Total Views:1142
- Region : North America
- GlobalData
- Equity Research Report
Details
Summary
Deciphera Pharmaceuticals LLC (Deciphera Pharmaceuticals) is a research and development company that develops, designs, and commercializes kinase inhibiting drugs. The company provides clinical pipeline of kinase inhibitors such as tumor-targeted therapies and immuno-targeted therapies. It uses proprietary switch control inhibitor platform for discovering and developing kinase inhibitors. Deciphera Pharmaceuticals products are used in the treatment of renal and colon cancers, mastocytosis, gastrointestinal stromal tumors, crohn's disease and autoimmune nephritis, solid tumors and rheumatoid arthritis, among others. The company's products are used in the treatment of immunological diseases and cancers. It markets its products through medical representatives. Deciphera Pharmaceuticals is headquartered in Waltham, Massachusetts, the US.
Deciphera Pharmaceuticals LLC (DCPH)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Deciphera Pharma Raises USD52 Million in series C Financing 11
Deciphera Pharma Raises USD15 Million in Extended Series B Financing 12
Deciphera Pharma Raises USD75 Million in Series B Financing Round 13
Deciphera Pharma Raises USD21.5 Million in Financing Round 14
Deciphera Pharma Raises USD90.6 Million in Financing Round 15
Equity Offering 16
Deciphera Pharma Plans to Raise up to USD400 Million in Public Offering of Securities 16
Deciphera Pharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD198 Million 17
Deciphera Pharma Raises USD127.5 in IPO 19
Deciphera Pharmaceuticals LLC-Key Competitors 21
Deciphera Pharmaceuticals LLC-Key Employees 22
Deciphera Pharmaceuticals LLC-Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Aug 07, 2018: Deciphera Pharmaceuticals announces second quarter 2018 financial results 24
May 08, 2018: Deciphera Pharmaceuticals Announces First Quarter 2018 Financial Results 26
Mar 28, 2018: Deciphera Pharmaceuticals Announces Fourth Quarter 2017 Financial Results and Corporate Highlights 27
Nov 14, 2017: Deciphera Pharmaceuticals Announces Third Quarter 2017 Financial Results and Corporate Highlights 29
Corporate Communications 30
May 29, 2018: Deciphera Pharmaceuticals Names Stephen B. Ruddy As Chief Technical Officer 30
May 21, 2018: Deciphera Pharmaceuticals Expands Board with the Election of Mr. Steven L. Hoerter as a Director 31
Product News 32
11/06/2017: Deciphera Pharmaceuticals to Report Clinical Data with DCC-2618 at the Upcoming 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology 32
Product Approvals 33
Nov 28, 2017: Deciphera Pharmaceuticals Announces Orphan Drug Designation from the EMA for DCC-2618 for the Treatment of Gastrointestinal Stromal Tumors 33
Sep 05, 2017: Deciphera Pharmaceuticals Announces FDA Orphan Drug Designation for DCC-2618 for the Treatment of Glioblastoma Multiforme and Anaplastic Astrocytoma 34
Clinical Trials 35
Jan 04, 2018: Deciphera Pharmaceuticals Initiates Phase 3 Clinical Study with DCC-2618 in Patients with Advanced Gastrointestinal Stromal Tumors ("INVICTUS study") 35
Nov 20, 2017: Deciphera Pharmaceuticals Reports Data from Ongoing Phase 1 Clinical Study of DCC-2618 at the 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology 36
Nov 10, 2017: Deciphera Pharmaceuticals Reports Data Analysis from the Ongoing Phase 1 Clinical Trial of DCC-2618 at the Annual Meeting of The Connective Tissue Oncology Society 37
Sep 11, 2017: Deciphera Pharmaceuticals Reports Updated Data from Ongoing Phase 1 Clinical Study of DCC-2618 at the European Society of Medical Oncology 2017 Congress 38
Aug 31, 2017: Deciphera Pharmaceuticals to Present Updated Data from Ongoing Phase 1 Study of DCC-2618 at the 2017 European Society for Medical Clinical Oncology Annual Congress 39
Jun 05, 2017: Deciphera Pharmaceuticals Reports Updated Phase 1 Clinical Study Results with DCC-2618 at 2017 American Society of Clinical Oncology Annual Meeting 40
May 18, 2017: Deciphera Pharmaceuticals to Report Phase 1 Clinical Study Results with DCC-2618 at the 2017 American Society of Clinical Oncology Annual Meeting 41
Apr 03, 2017: Translational Research Results Confirm The Broad Activity of DCC-2618 in GIST Patients With Difficult to Treat Drug Resistant KIT Mutations 42
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43
List Of Figure
List of Figures
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List Of Table
List of Tables
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Deciphera Pharmaceuticals LLC, Deals By Therapy Area, 2012 to YTD 2018 9
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Deciphera Pharma Raises USD52 Million in series C Financing 11
Deciphera Pharma Raises USD15 Million in Extended Series B Financing 12
Deciphera Pharma Raises USD75 Million in Series B Financing Round 13
Deciphera Pharma Raises USD21.5 Million in Financing Round 14
Deciphera Pharma Raises USD90.6 Million in Financing Round 15
Deciphera Pharma Plans to Raise up to USD400 Million in Public Offering of Securities 16
Deciphera Pharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD198 Million 17
Deciphera Pharma Raises USD127.5 in IPO 19
Deciphera Pharmaceuticals LLC, Key Competitors 21
Deciphera Pharmaceuticals LLC, Key Employees 22
Deciphera Pharmaceuticals LLC, Other Locations 23
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Deciphera Pharmaceuticals LLC, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
Deciphera Pharmaceuticals LLC (Deciphera Pharmaceuticals) is a research and development company that develops, designs, and commercializes kinase inhibiting drugs. The company provides clinical pipeline of kinase inhibitors such as tumor-targeted therapies and immuno-targeted therapies. It uses proprietary switch control inhibitor platform for discovering and developing kinase inhibitors. Deciphera Pharmaceuticals products are used in the treatment of renal and colon cancers, mastocytosis, gastrointestinal stromal tumors, crohn's disease and autoimmune nephritis, solid tumors and rheumatoid arthritis, among others. The company's products are used in the treatment of immunological diseases and cancers. It markets its products through medical representatives. Deciphera Pharmaceuticals is headquartered in Waltham, Massachusetts, the US.
Deciphera Pharmaceuticals LLC (DCPH)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Deciphera Pharma Raises USD52 Million in series C Financing 11
Deciphera Pharma Raises USD15 Million in Extended Series B Financing 12
Deciphera Pharma Raises USD75 Million in Series B Financing Round 13
Deciphera Pharma Raises USD21.5 Million in Financing Round 14
Deciphera Pharma Raises USD90.6 Million in Financing Round 15
Equity Offering 16
Deciphera Pharma Plans to Raise up to USD400 Million in Public Offering of Securities 16
Deciphera Pharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD198 Million 17
Deciphera Pharma Raises USD127.5 in IPO 19
Deciphera Pharmaceuticals LLC-Key Competitors 21
Deciphera Pharmaceuticals LLC-Key Employees 22
Deciphera Pharmaceuticals LLC-Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Aug 07, 2018: Deciphera Pharmaceuticals announces second quarter 2018 financial results 24
May 08, 2018: Deciphera Pharmaceuticals Announces First Quarter 2018 Financial Results 26
Mar 28, 2018: Deciphera Pharmaceuticals Announces Fourth Quarter 2017 Financial Results and Corporate Highlights 27
Nov 14, 2017: Deciphera Pharmaceuticals Announces Third Quarter 2017 Financial Results and Corporate Highlights 29
Corporate Communications 30
May 29, 2018: Deciphera Pharmaceuticals Names Stephen B. Ruddy As Chief Technical Officer 30
May 21, 2018: Deciphera Pharmaceuticals Expands Board with the Election of Mr. Steven L. Hoerter as a Director 31
Product News 32
11/06/2017: Deciphera Pharmaceuticals to Report Clinical Data with DCC-2618 at the Upcoming 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology 32
Product Approvals 33
Nov 28, 2017: Deciphera Pharmaceuticals Announces Orphan Drug Designation from the EMA for DCC-2618 for the Treatment of Gastrointestinal Stromal Tumors 33
Sep 05, 2017: Deciphera Pharmaceuticals Announces FDA Orphan Drug Designation for DCC-2618 for the Treatment of Glioblastoma Multiforme and Anaplastic Astrocytoma 34
Clinical Trials 35
Jan 04, 2018: Deciphera Pharmaceuticals Initiates Phase 3 Clinical Study with DCC-2618 in Patients with Advanced Gastrointestinal Stromal Tumors ("INVICTUS study") 35
Nov 20, 2017: Deciphera Pharmaceuticals Reports Data from Ongoing Phase 1 Clinical Study of DCC-2618 at the 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology 36
Nov 10, 2017: Deciphera Pharmaceuticals Reports Data Analysis from the Ongoing Phase 1 Clinical Trial of DCC-2618 at the Annual Meeting of The Connective Tissue Oncology Society 37
Sep 11, 2017: Deciphera Pharmaceuticals Reports Updated Data from Ongoing Phase 1 Clinical Study of DCC-2618 at the European Society of Medical Oncology 2017 Congress 38
Aug 31, 2017: Deciphera Pharmaceuticals to Present Updated Data from Ongoing Phase 1 Study of DCC-2618 at the 2017 European Society for Medical Clinical Oncology Annual Congress 39
Jun 05, 2017: Deciphera Pharmaceuticals Reports Updated Phase 1 Clinical Study Results with DCC-2618 at 2017 American Society of Clinical Oncology Annual Meeting 40
May 18, 2017: Deciphera Pharmaceuticals to Report Phase 1 Clinical Study Results with DCC-2618 at the 2017 American Society of Clinical Oncology Annual Meeting 41
Apr 03, 2017: Translational Research Results Confirm The Broad Activity of DCC-2618 in GIST Patients With Difficult to Treat Drug Resistant KIT Mutations 42
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43
List Of Figure
List of Figures
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List Of Table
List of Tables
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Deciphera Pharmaceuticals LLC, Deals By Therapy Area, 2012 to YTD 2018 9
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Deciphera Pharma Raises USD52 Million in series C Financing 11
Deciphera Pharma Raises USD15 Million in Extended Series B Financing 12
Deciphera Pharma Raises USD75 Million in Series B Financing Round 13
Deciphera Pharma Raises USD21.5 Million in Financing Round 14
Deciphera Pharma Raises USD90.6 Million in Financing Round 15
Deciphera Pharma Plans to Raise up to USD400 Million in Public Offering of Securities 16
Deciphera Pharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD198 Million 17
Deciphera Pharma Raises USD127.5 in IPO 19
Deciphera Pharmaceuticals LLC, Key Competitors 21
Deciphera Pharmaceuticals LLC, Key Employees 22
Deciphera Pharmaceuticals LLC, Other Locations 23
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Deciphera Pharmaceuticals LLC, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Ask A Question
Our Team Will Assist You in What You Are Looking For
or 
: +91 98100 26150
: ankurgupta1984
Related Reports
Page 130 | 
December 2020
Page 130 | December 2020
Page 131 | November 2020
Page 95 | November 2020
Page 96 | August 2020